are winners!

Top News

Martinsried/ Munich (06.11.2019) - Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene's DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA. The poster entitled "DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment" will be presented by Medigene's ... [ more ]